DNA Script Signs Innovation Development Contract With French Defence Innovation Agency to Enable On-Demand Diagnostics Against Emerging Biothreats
DNA Script, a leading pioneer in enabling DNA synthesis on demand, today announced a partnership with the French Defence Innovation Agency, in liaison with the French Armament General Directorate (DGA), to develop a prototype for rapid mobile manufacturing of DNA primers and probes, key components of detection and diagnostic tests for pathogens. The joint project will employ DNA Script’s novel enzymatic synthesis platform to quickly generate high-fidelity nucleic acids. The prototypes to be developed by DNA Script will be evaluated by the DGA. As part of the agreement, DNA Script will receive $1.6 million in funding.
In an emerging biothreat, like the ongoing COVID-19 pandemic, conventional sources of supply for key reagents (qPCR primers and probes in particular) become a limiting factor. Therefore, it is essential to enable an on-demand, agile source for custom reagent manufacturing. The DGA identified DNA Script’s SYNTAX™ platform, a benchtop instrument that synthesizes high-quality, custom nucleic acids in hours, a key capability that enables scientists to iterate faster in response to emerging biothreats, as a potential solution. The underlying core technology, enzymatic DNA synthesis, mimics the enzymatic process used by nature, thus avoiding the use of harsh organic solvents or the need to avoid the presence of air or water as required by conventional chemical approaches commercially available today.
DNA Script will adapt its SYNTAX™ platform to enable the synthesis of the DNA reagents such as Taqman probes, required in PCR-based molecular biology diagnostics. SYNTAX™ is the world’s first instrument to use an enzymatic process for nucleic acid synthesis.
“We are thrilled to collaborate with the French Ministry for Armed Forces on this important initiative to rapidly detect, characterize and mitigate threats from newly emerging or engineered pathogens,” said Thomas Ybert, Chief Executive Officer of DNA Script. “We believe that the speed, efficiency and ease of use of our SYNTAX™ nucleic acid printer and underlying enzymatic synthesis technology will be critical in addressing future pandemics.”
About DNA Script
Founded in 2014 in Paris, DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, making this technology accessible to labs with the world’s first benchtop enzymatic synthesis instrument, SYNTAX™. By putting DNA synthesis back in the lab, DNA Script is transforming life science research through innovative technology that gives researchers unprecedented autonomy. www.dnascript.com
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UPF3.3.2021 19:45:03 CET | Press release
Universal Peace Federation: Millions of participants from 150 countries joined the live online broadcast of the 5th Rally of Hope
GA-AGCO3.3.2021 17:52:07 CET | Press release
AGCO Announces Farmer-First Strategy
IL-MOTOROLA-SOLUTIONS3.3.2021 17:29:05 CET | Press release
Norwegian Emergency Health Services Gain Nationwide Collaboration Through Motorola Solutions’ Unified Control Room Solution
H.I.G.-CAPITAL3.3.2021 17:10:14 CET | Press release
H.I.G. Capital Expands European WhiteHorse Team with the Addition of Michael Lucas
NZMP3.3.2021 17:02:13 CET | Press release
NZMP™ Customers Set to Benefit From New Carbonzero Certified Ingredients
CQN-MONUMENT-RE-LIMITED3.3.2021 16:09:07 CET | Press release
CORRECTING and REPLACING Monument Re Acquires Variable Annuity Portfolio From Athora Ireland Plc.
ALTASCIENCES3.3.2021 15:43:06 CET | Press release
Altasciences Conducts Phase I Study in Healthy Normal Subjects for RLS-0071 for Treatment of Acute Lung Injury Due to COVID-19 Pneumonia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom